期刊: LANCET ONCOLOGY, 2021; 22 (8)
Background The addition of camrelizumab to gemcitabine and cisplatin showed promising activity as first-line therapy in patients with recurrent or met......
期刊: LANCET ONCOLOGY, 2021; 22 (4)
Background The benefits of secondary cytoreduction for platinum-sensitive relapsed ovarian cancer are still widely debated. We aimed to assess the eff......
期刊: LANCET ONCOLOGY, 2021; 22 (8)
Background There is paucity of investigations into immunotherapy or targeted therapy for postoperative locally recurrent pancreatic cancer. We aimed t......
期刊: LANCET ONCOLOGY, 2021; 22 (7)
Background China has a high burden of hepatocellular carcinoma, and hepatitis B virus (HBV) infection is the main causative factor. Patients with hepa......
期刊: LANCET ONCOLOGY, 2021; 22 (8)
Epithelial-mesenchymal transition (EMT) is a process during which cells lose their epithelial characteristics, for instance apical-basal cell polarity......
期刊: LANCET ONCOLOGY, 2021; 22 (5)
Background Cisplatin-based induction chemotherapy plus concurrent chemoradiotherapy in the treatment of patients with locoregionally advanced nasophar......